Alternative multidrug regimen provides improved suppression of HIV-1 replication over triple therapy

AIDS

Volumn 12, Issue 11, 1998, Pages

  Weverling, Gerrit J ^a   Lange, Joep M A ^a   Jurriaans, Suzanne ^b   Prins, Jan M ^a   Lukashov, Vladimir V ^b   Notermans, Daan W ^a   Roos, Marijke ^c   Schuitemaker, Hanneke ^c   Hoetelmans, Richard M W ^d   Danner, Sven A ^a   Goudsmit, Jaap ^b   De Wolf, Frank ^b  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

^c CENTRAL LABORATORY   (Netherlands)

^d SLOTERVAART HOSPITAL   (Netherlands)

Author keywords

Antiretroviral therapy; HIV 1 RNA elimination rate constants; HIV 1 RNA suppression; Multidrug therapy

Indexed keywords

ABACAVIR; ANTIRETROVIRUS AGENT; INDINAVIR; LAMIVUDINE; NEVIRAPINE; RITONAVIR; VIRUS RNA; ZIDOVUDINE;

ANTIVIRAL ACTIVITY; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; PRIORITY JOURNAL; REGRESSION ANALYSIS; VIRUS REPLICATION;

EID: 15144339718     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-199811000-00003     Document Type: Article

References (29)

1. Danner SA, Carr A, Leonard JM, et al.: A short-term study of the safety, pharmaco-kinetics, and efficacy of ritonavir, an inhibitor of HIV-1 protease. N Engl J Med 1995, 333:1528-1533.
2. Markowitz M, Saag M, Powderly WG, et al.: A preliminary study of ritonavir, an inhibitor of HIV-1 protease, to treat HIV-1 infection. N Engl J Med 1995, 333:1534-1539.
3. Carpenter CJ, Fischl MA, Hammer SM, et al.: Antiretroviral therapy for HIV infection in 1997: update recommendations of the International AIDS Society-USA Panel. J Am Med Assoc 1997, 277:1962-1969.
4. Hammer SM, Squires KE, Hughes MD, et al.: A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. N Engl J Med 1997, 337:725-733.
5. Gulick RM, Mellors JW, Havlir D, et al.: Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. N Engl J Med 1997, 337:734-739.
6. Shirasaka T, Chokekijchai S, Yamada A, Gosselin G, Imbach J-L, Mitsuya H: Comparative analysis of anti-human immunodeficiency virus type 1 activities of dideoxynucleoside analogs in resting and activated peripheral blood mononuclear cells. Antimicrob Agents Chemother 1995, 39:2555-2559.
7. Van't Wout AB, Ran LJ, de Jong M, et al.: Selective inhibition of SI and NSI HIV-1 variants by ddl and zidovudine respectively, may contribute to the enhanced clinical benefit of ZDV/ddl combination therapy. J Clin Invest 1997, 100:2325-2332.
8. Havlir D, Cheeseman SH, Mclaughlin M, et al.: High-dose nevirapine: safety, pharmacokinetics, and antiviral effect in patients with human immunodeficiency virus infection. J Infect Dis 1995, 171:537-545.
9. Wei X, Ghosh SK, Taylor ME, et al.: Viral dynamics in human immunodeficiency virus type 1 infection. Nature 1995, 373:117-122.
10. Hammer SM, Katzenstein DA, Hughes MD, et al.: A trial comparing nucleoside monotherapy with combination therapy in HIV-infected adults with CD4 cell counts from 200 to 500 per cubic millimeter. N Engl J Med 1996, 335:1081-1090.
11. Delta Coordinating Committee: Delta: a randomised double-blind controlled trial comparing combinations of zidovudine plus didanosine or zalcitabine with zidovudine alone in HIV-infected individuals. Lancet 1996, 348:283-291.
12. Katlama C, Ingrand D, Loveday C, et al.: Safety and efficacy of lamivudine zidovudine combination therapy in antiretroviral naive patients: a randomized controlled comparison with zidovudine monotherapy. JAMA 1996, 276:118-125.
13. Eron JJ, Benoit SL, Jemsek J, et al.: Treatment with lamivudine, zidovudine, or both in HIV-positive patients with 200 to 500 CD4+ cells per cubic millimeter. N Engl J Med 1995, 333:1662-1669.
14. 3. 3rd Conference on Retroviruses and Opportunistic Infections. Washington DC, January-February, 1996 [abstract 195].
15. Cavert W, Notermans DW, Staskus K, et al.: Kinetics of response in lymphoid tissues to antiretroviral therapy of HIV-1 infection. Science 1997, 276:960-964.
16. Notermans DW, Jurriaans S, de Wolf F, et al.: Decrease of plasma HIV-1 RNA levels in lymphoid tissue and peripheral blood during treatment with ritonavir, lamivudine and zidovudine. AIDS 1998, 12:167-173.
17. Goebel F, the Avanti Study Croup: Avanti 2. A randomised, double-blind, comparative trial to evaluate combination antiretroviral regimens for the treatment of HIV-1 infection: AZT/3TC vs AZT/3TC/indinavir in antiretroviral naive patients. Sixth European Conference on Clinical Aspects and Treatment of HIV-Infection. Hamburg, October 1997 [abstract 211].
18. Yu G, Greenberg SL, Clendeninn NJ: Durability of virological response in patients with Viracept (nelfinavir mesylate) in combination with zidovudine and lamivudine. Sixth European Conference on Clinical Aspects and Treatment of HIV-Infection. Hamburg, October 1997 [abstract 410].
19. Emini EA: Evidence for the prevention of new HIV-1 infection cycles in patients treated with indinavir plus zidovudine plus lamivudine [abstract]. Antiviral Ther 1997, 2 (suppl 5):S117.
20. Montaner JSG, Raboud JM, Rae S, et al.: Full suppression of viral replication to below 20 copies/ml is needed to achieve a durable antiviral response. Sixth European Conference on Clinical Aspects and Treatment of HIV-Infection. Hamburg, October 1997 [abstract 105].
21. Wong JK, Günthard HF, Havlir D, et al.: Reduction of HIV-1 in blood and lymph nodes following potent antiretroviral therapy and the virologic correlates of treatment failure. Proc Natl Acad Sci USA 1997, 94:12574-12579.
22. Condra JH, Schleif WA, Blahy OM, et al.: In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors. Nature 1995, 374:569-571.
23. Havlir D, Richman DD: Non-nucleoside reverse transcriptase inhibitors - clinical aspects. In Antiviral Drug Resistance. Edited by Richman DD. Chichester: Wiley & Sons, 1996:241-260.
24. D'Aquila RT. Nucleosides and foscarnet-clinical aspects. In Antiviral Drug Resistance. Edited by Richman DD. Chichester: Wiley & Sons, 1996:191-223.
25. Lange JMA: Current problems and the future of antiretroviral drug trials. Science 1997, 276:548-550.
26. Lange JMA, Richman DD: The first blow is half the battle. Antiviral Ther 1997, 2:132-133.
27. Chun T-W, Carruth L, Finzi D, et al.: Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection. Nature 1997, 387:183-188.
28. Wong JK, Hezareh M, Günthard HF, et al.: Recovery of replication-competent HIV despite prolonged suppression of plasma viremia. Science 1997, 278:1291-1295.
29. Finzi D, Hermankova M, Pierson T, et al.: Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science 1997, 278:1295-1300.